Eton Pharmaceuticals, Inc.
ETON
$16.90
-$2.24-11.70%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 18.65% | 9.52% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 18.65% | 9.52% | |||
| Cost of Revenue | 129.08% | -21.88% | |||
| Gross Profit | -30.10% | 33.16% | |||
| SG&A Expenses | -16.32% | 5.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.20% | 8.13% | |||
| Operating Income | 85.45% | 42.98% | |||
| Income Before Tax | 22.39% | -68.16% | |||
| Income Tax Expenses | -142.42% | -10.81% | |||
| Earnings from Continuing Operations | 25.45% | -64.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 25.45% | -64.44% | |||
| EBIT | 85.45% | 42.98% | |||
| EBITDA | 31.61% | 35.73% | |||
| EPS Basic | 25.39% | -64.27% | |||
| Normalized Basic EPS | 51.80% | 12.36% | |||
| EPS Diluted | 28.30% | -70.94% | |||
| Normalized Diluted EPS | 51.80% | 12.36% | |||
| Average Basic Shares Outstanding | 0.00% | 0.02% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||